// App-Quantinova.ai

P593 : Hospital resource use and cost associated with first-line anti-TNF therapy in patients with IBD in the UK: comparison of subcutaneous (adalimumab) and intravenous (infliximab) therapies

Researchers

Presenter

  • J. Hickey

Principal Investigators

  • S. Keshav

  • S. Gaugris

  • R. Arasaradnam

Medical Centers

  • pH Associates Ltd, Marlow, United Kingdom

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • John Radcliffe Hospital, Department of Gastroenterology, Oxford, United Kingdom

  • AbbVie Ltd, Maidenhead, United Kingdom

  • University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

  • Infliximab

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved